top of page
Aducanumab and Persons with Down Syndrome: What Do We Do Now?

Aducanumab and Persons with Down Syndrome: What Do We Do Now?

Resource document

NTG issued statement on use of Aduhelm by persons with Down syndrome. This statement, the result of a collaborative effort coordinated by the NTG Aduhelm and Down Syndrome Medical Advisory Group, was led by Seth M. Keller, MD, Co-President of the National Task Group on Intellectual Disabilities and Dementia Practices.

bottom of page